Search Within

Robert Maki

Formats
  1. Journal Article (140)
  2. Meeting Abstract (85)
  3. Book Section (7)
  4. Editorial (6)
  5. Review (2)
Groups
  1. Tow Center for Developmental Oncology (TCDO) (100)
  2. GSK Faculty (98)
  3. Surgery (81)
  4. Department of Pathology and Laboratory Medicine (79)
  5. Department of Medicine (68)
  6. Sarcoma Surgeons (66)

More Groups

People
  1. Cristina Antonescu (72)
  2. Samuel Singer (49)
  3. Murray Brennan (38)
  4. Gary Schwartz (32)
  5. Mary Keohan (32)
  6. David D'Adamo (27)

More People

Years
  1. 2025 (4)
  2. 2024 (17)
  3. 2023 (4)
  4. 2015 (1)
  5. 2014 (2)
  6. 2013 (7)

More Years

Publications
  1. Journal of Clinical Oncology (75)
  2. Clinical Cancer Research (22)
  3. Annals of Oncology (17)
  4. Cancer (8)
  5. Annals of Surgical Oncology (7)
  6. Cancer Research (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (76)
  2. American Association for Cancer Research (28)
  3. Oxford University Press (22)
  4. Springer (18)
  5. Elsevier Inc. (14)
  6. Lippincott Williams & Wilkins (11)

More Publishers

Results (240)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers
    Journal Article

    Chen, J.; Guo, T.; Zhang, L.; Qin, L. X.; Singer, S.; Maki, R. G.; Taguchi, T.; DeMatteo, R.; Besmer, P.; Antonescu, C. R.
    Genes Chromosomes and Cancer (2012)

    Fulltext@MSK | Save
  • Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival
    Meeting Abstract

    Toulmonde, M.; Italiano, A.; Penel, N.; Cioffi, A.; Le Cesne, A.; Isambert, N.; Bompas, E.; Duffaud, F.; Patrikidou, A.; Maki, R. G.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial
    Meeting Abstract

    Schwartz, G. K.; Maki, R. G.; Ratain, M. J.; Undevia, S. D.; Jones, R. L.; Rudin, C. M.; Siu, L. L.; Brockstein, B.; Khayat, D.; Gil, T.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls
    Meeting Abstract

    Shaw, A. T.; Yeap, B. Y.; Solomon, B. J.; Riely, G. J.; Iafrate, A. J.; Shapiro, G.; Costa, D. B.; Butaney, M.; Ou, S. I.; Maki, R. G.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial
    Meeting Abstract

    Kindler, H. L.; Campbell, N. P.; Wroblewski, K.; Maki, R. G.; D'Adamo, D. R.; Chow, W. A.; Gandara, D. R.; Antonescu, C.; Stadler, W. M.; Vokes, E. E.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib
    Meeting Abstract

    Italiano, A.; Cioffi, A.; Maki, R. G.; Schoffski, P.; Rutkowski, P.; Le Cesne, A.; Duffaud, F.; Adenis, A.; Isambert, N.; Bompas, E.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival
    Meeting Abstract

    Cioffi, A.; Italiano, A.; Penel, N.; Berge, Y.; Toulmonde, M.; Salas, S.; Chevreau, C.; Le Cesne, A.; Duffaud, F.; D'Adamo, D. R.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST)
    Meeting Abstract

    D'Adamo, D. R.; Keohan, M. L.; Carvajal, R. D.; Hensley, M. L.; Hirst, C.; Qin, L.; Antonescu, C.; Lefkowitz, R. A.; Schwartz, G. K.; Maki, R. G.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Camidge, D. R.; Bang, Y.; Kwak, E. L.; Shaw, A. T.; Iafrate, A. J.; Maki, R. G.; Solomon, B. J.; Ou, S. I.; Salgia, R.; Wilner, K. D.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors
    Meeting Abstract

    Beryozkina, A.; Nichols, G. L.; Reckner, M.; Vassilev, L. T.; Rueger, R.; Jukofsky, L.; Middleton, S.; Andreeff, M.; Padmanabhan, S.; Strair, R.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save